Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its resources on divesiran, which it is testing for polycythemia vera and other hematologic indications.

Scroll to Top